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STAT transcription factors are regulators of critical cellular
processes such as proliferation, survival, and self-renewal.
While the activity of these proteins is tightly regulated under
physiological conditions, they can become constitutively
activated in a broad range of human cancers. This inappro-
priate STAT activation leads to enhanced transcription of
genes that can directly lead to the malignant phenotype. Since
STATs are largely dispensable for normal cell function, this has
raised the possibility that STATs might be key targets for
cancer therapy. Although a number of structure-based
strategies have been used to develop STAT inhibitors, an
alternate approach is to use cell-based assays that make use of
the transcriptional function of STATs. Employing these
systems, one can screen large chemical libraries to identify
compounds that specifically block the function of a given
STAT. This approach can lead to the identification of
compounds that inhibit STATs by a variety of mechanisms,
and can suggest novel targets for therapy. This type of
functional screening strategy has already identified a drug that
potently inhibits STAT3, and which is now being evaluated in a
clinical trial for patients with chronic lymphocytic leukemia.
Introduction
Targeted therapy in cancer. After the burst of enthusiasm that
followed the clinical development of imatinib mesylate (Gleevec)
for the treatment of chronic myelogenous leukemia (CML),
1 the
clinical impact of targeted therapies for cancer has proceeded at a
much more measured pace. This has reflected a number of factors.
First, CML is unique, in that its pathogenesis is driven both by
the uniform presence of the Bcr-Abl1 fusion tyrosine kinase as
well as the critical dependence of the leukemic cells on this one
oncogenic event.
2 In many other common cancers, tyrosine
kinases activated through mutation, fusion or overexpression have
been discovered. However, any one oncogenic kinase is much less
prevalent. For example, Her2 overexpression in breast cancer,
EGF receptor mutation in lung cancer or Flt3 mutation in acute
myelogenous leukemia (AML) occur in no more than 20 to 30%
of patients. Furthermore, while these oncogenic kinases clearly
contribute to the pathogenesis of these cancers, the tumors are not
completely dependent on them. Consequently, inhibition of their
kinase activity or targeting their extracellular component with
antibodies confers only limited therapeutic benefit. Even in cases
where kinase inhibition does show efficacy, the rapid emergence
of resistance is a recurrent finding and limits the clinical utility. It
is becoming increasingly apparent that activation of parallel
pathways is a common mechanism by which resistance to kinase
inhibitors occurs.
However, the experience gleaned from the clinical development
of kinase inhibitors during the past 15 years has provided several
key insights. First, targeted kinase inhibitors will only be useful in
a small fraction of patients with a given form of cancer. This can
still be a powerful approach; for example, although fewer than 5%
of patients with non-small cell lung cancer display ALK kinase
activation, a high proportion have achieved dramatic results with
the ALK inhibitor crizotinib.
3 However, it will require that this
type of “personalized medicine” be focused on relatively small
subsets of patients. Second, kinase inhibitors and other targeted
therapies will almost certainly need to be used in combination
with other therapies, both to achieve maximal responses (as with
monoclonal antibodies such as trastuzumab to Her2 or rituximab
to CD20) and to forestall resistance.
These findings have raised the question of whether there is a
common convergence point downstream of a variety of kinases
and other signaling pathways activated by mutation, such as Ras,
Raf or PI3-kinase, which may be targeted therapeutically.
Ultimately, these signaling pathways exert most of their effects
by regulating the expression or function of transcription factors.
In this way, they modulate the expression of genes controlling
important cellular processes such as proliferation, survival,
invasion and metastasis. Since these oncogenic transcription
factors are downstream of a large number of pathways activated
through mutations, targeting these proteins holds the promise of
extending personalized cancer therapy to a much larger fraction of
cancer patients. Furthermore, given the fact that resistance to
targeted kinase inhibitors often arises through activation of
complementary signaling pathways, targeting transcription factors
holds tremendous promise both alone and in conjunction with
kinase inhibitors.
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292 JAK-STAT Volume 1 Issue 4STATs as oncogenic transcription factors. Under physio-
logical conditions, transcription factors are generally activated
rapidly and transiently in response to cytokines and other stimuli.
This allows for tight regulation of the expression of genes whose
protein products regulate critical processes such as proliferation,
survival, differentiation and invasion. One such group of critical
regulators are the STATs, which mediate the effects of a wide
variety of cytokines from interferons, to hematologic regulators, to
inflammatory mediators.
4 Shortly after it became apparent that
some family members, like STAT3 and STAT5, were important
in signals triggered by hematopoietic growth factors such as
erythropoietin and interleukin (IL)-2, it was found that
constitutive activation of these proteins is an extremely common
finding in nearly all human cancers.
5 Consistent with the
prediction that oncogenic transcription factors are activated
downstream of many activated tyrosine kinases, STATs are
activated much more commonly than any single genetic driver
mutation.
6 For example, in breast cancer, the most commonly
activated tyrosine kinase is Her2, whose increased expression and
functional activation is driven by genetic amplification. Whereas
Her2 is amplified in approximately 25 to 30% of patients, STAT3
is activated constitutively in approximately 70% of patients.
7
Thus, while individual analysis is necessary to determine which
patients may benefit from STAT3 inhibition, targeting STAT3 or
other STAT family members will likely have widespread
applicability.
The final consideration in developing an anti-cancer therapy
concerns the therapeutic index. While a drug may inhibit a
pathway critical for cancer cell proliferation or survival, it is
equally important that it not be toxic to normal cells. Evidence
from experimental systems to human genetic analyses has
provided strong support for the contention that the activity of
specific STAT family members can be lost from normal cells
without severe consequence, likely due to redundancies in
transcriptional regulation under physiological conditions.
8,9
Taken together, these findings have suggested that STATs may
be particularly worthwhile targets for cancer therapy.
Strategies for Targeting STATs
It has often been argued that transcription factors are not optimal
targets for pharmacological inhibition, because their function is
not dependent on small surfaces or pockets to which drug-like
organic molecules can bind. However, STATs clearly have
discrete domains necessary for their function, including the
SH2, DNA binding and N-terminal oligomerization domains.
10
These sites can certainly be blocked using a number of strategies,
and hold promise for therapeutic development.
Screening approaches to identify STAT inhibitors. An
alternate approach to structure-based design of STAT inhibitors
is to develop an assay that makes use of the transcriptional activity
of a specific STAT. One can then screen compounds for their
ability to inhibit that transcriptional function while leaving
unaffected transcription factors analyzed in a counter-screen.
11
Such an assay would allow the analysis of large chemical libraries
for STAT inhibitory activity. This is particularly appealing as
many natural products and their derivatives have been found to
block STAT3 activation, including the green tea component
epigallocatechin-3-gallate (EGCG),
12 curcumin, which is an
extract of the Indian spice turmeric,
13 and triterpenoids.
14
Although all of these compounds have other effects on cellular
signaling as well, their anti-cancer effects appear to be mediated, at
least in part, through their suppression of STAT3-dependent gene
expression. Thus, compounds such as these might well be
identified through STAT3-dependent screening systems.
One such screening approach to identify inhibitors of STAT3,
which is activated widely in human cancers, utilizes a luciferase
reporter gene under the control of a high-affinity STAT3-
responsive promoter.
15 When cells stably transfected with this
construct are stimulated with a cytokine that activates STAT3
such as IL-6, luciferase is generated which can be detected by
luminometry. This type of strategy is suitable for use in multi-well
plates, which allows for high throughput screening of chemical
libraries. Many cytokines that activate STAT3, particularly those
like IL-6 that signal through the gp130 receptor chain, lead to the
activation of STAT1 as well. Since these STATs can bind to the
same regulatory elements, this can make it difficult to discern
effects related to one STAT vs. the other. To circumvent this
problem, human fibrosarcoma cells that lack STAT1 have been
used in this system, thereby assuring that all of the transcriptional
effects were mediated by STAT3.
Finally, a key component of a screening system such as this is to
include a counter-screen to exclude compounds that decrease
luciferase activity through a trivial mechanism, such as non-
specific cytotoxicity, or global effects on transcription or
translation. One such approach is to screen in parallel a cell line
in which luciferase activity is under the control of another
transcription factor, such as NFkB( Fig.1).
When a chemical library, such as the Prestwick collection of
approximately 1,200 compounds, is screened with the STAT3
reporter system, the vast majority of compounds have no
significant effect on STAT3-dependent luciferase expression
(Fig.2).
16 Fewer than 10% decrease STAT3 activity by greater
than 25%. However, to exclude non-specific effects, a parallel
counter-screen is performed on a similar NFkB-dependent system
(Fig.3). In general, there is little correlation between the effects of
compounds in the two assays. However, among the compounds
that have the greatest inhibitory effect in the STAT3 assay, many
have inhibitory effects in the NFkB assay as well. These
compounds most likely are exerting their effects through non-
specific mechanisms, and in fact, many are DNA damaging agents
and protein synthesis inhibitors. However, a small fraction has
significant inhibitory effects in the STAT3 system, and little to no
effects in the NFkB system, and these are candidates for further
validation.
One major strength of this approach is that it views STAT3-
dependent transcription from a systems level. This allows effective
and specific inhibitors of STAT3 to be discovered that may not
directly interact with STAT3 or classical components of the JAK-
STAT pathway. For example, if a small molecule specifically
inhibited a component of a nuclear import channel that only
affected STAT3 dimers, then it would score as a hit. This method
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modulation. Another strength of this approach is that it can also
uncover molecules that directly activate or enhance the activation
of STAT3 (Fig.2). While that might not be the direct interest for
cancer therapy, it can reveal several key features of STAT
signaling. First, it might reveal negative regulators of STAT3
signaling that are important for the biology of this pathway. In
addition, activation of STAT3 could be desirable in some
situations. For example, increased STAT3 function may protect
cardiomyocytes during cardiac ischemia,
17 and thus could be a
protectant during a myocardial infarction. STAT3 activation may
have similar effects in neuronal protection during ischemic
stroke.
18 Finally, maintaining the pluripotency of embryonic stem
(ES) cells can require STAT3 activation,
19 and thus a STAT3
activator holds the potential to be important in maintaining ES
cells in an undifferentiated state without the need for additional
components.
This type of screening strategy also has several shortcomings.
First, even if a molecule is uncovered that is a potent and specific
inhibitor of STAT3, it can be quite laborious to deconvolute its
direct mechanism of action. Although initial biochemical and
cellular assays focus on questions such as whether the molecule
affects STAT3 tyrosine (or serine) phosphorylation, nuclear
localization, DNA binding or transcriptional co-activator recruit-
ment, it may still be difficult to identify the proximal molecular
target of an active compound. A second potential shortcoming
relates to the mechanism for activating STAT3 in the assay. The
use of a cytokine such as IL-6 allows for tightly controlled
induction of STAT3 activation during the assay, both in terms of
kinetics and amplitude. This is not irrelevant to the constitutive
activation of STAT3 occurring in cancer cells, which may be
driven by autocrine or paracrine loops involving IL-6 in
both epithelial cancers, like breast cancer, and hematological
Figure1. A cell-based screening assay can be designed to test for STAT3
inhibitors in chemical libraries. In one such system, a luciferase reporter
gene is ligated to a STAT3-dependent regulatory region, and stably
transfected into a cell line (A). When cells are treated with a cytokine that
can induce the activation of STAT3, such as IL-6, luciferase is expressed,
and its activity can be quantitated by luminometry. In the presence of a
STAT3 inhibitor, the induction of luciferase does not occur. To exclude
the identification of compounds that are inhibiting STAT3 through a
non-specific mechanism, a “counter-screen” is performed on a parallel
cell line in which luciferase expression is under the control of an NFkB-
responsive promoter that can be induced by tumor necrosis factor (TNF)-
a (B). Only compounds that inhibit STAT3-dependent transcription, but
not NFkB-dependent transcription, proceed to further validation. This
system can also identify compounds that are specific NFkB inhibitors.
Figure2. High throughput chemical library screen using a STAT3-
dependent luciferase reporter cell line. A value of 1 (black line)
represents no change from vehicle-treated cells. Only a small fraction of
compounds change IL-6 induced STAT3-dependent luciferase activity by
more than 25% (red lines). Of those that do, most are inhibiting
luciferase activity, although a small number enhance IL-6 induced
luciferase activity.
Figure3. High throughput chemical library screen using an NFkB-
dependent luciferase reporter cell line. Compounds are numbered as in
Figure2. Overall, there is a low correlation between activity in the NFkB-
dependent assay and the STAT3-dependent assay (Fig.2). Of the
compounds that are inhibitory in the STAT3 assay (compounds 1
through 70), many are inhibitory in the NFkB assay as well, and are likely
non-specific. However, a small fraction have no significant effect in the
NFkB assay (red oval), and these compounds are appropriate for further
validation.
294 JAK-STAT Volume 1 Issue 4malignancies such as multiple myeloma.
20 However, it is possible
that active compounds identified in this assay may be specific to
IL-6 rather than STAT3.
The final potential shortcoming that should be noted relates to
the fact that STAT3 may have important biological effects
independent of its ability to regulate gene expression. For
example, STATs can associate with the cytoskeleton, and may
play an important role in cell motility.
21,22 In addition, there is
evidence that, at least in certain systems, mitochondrial function-
ing of STAT3 is critical to tumorigenesis, independent of STAT3
tyrosine phosphorylation, nuclear localization or transcriptional
modulation. This function of STAT3 may be particularly
important in neoplastic transformation mediated by activated
Ras.
23 Compounds identified in a transcription-based screen may
not modulate the cytoskeletal or mitochondrial function of
STAT3, although a transcription-based assay may still be able to
detect compounds that affect these other aspects of STAT
function. For example, the mitochondrial effects of STAT3
appear to require the phosphorylation of STAT3 on serine 727.
Although there is conflicting evidence, phosphorylation of this
serine residue may also contribute to the transcriptional function
of STAT3,
24,25 and thus it is possible that some compounds
identified in this type of screen would affect both mitochondrial
and transcriptional functions of STAT3. Similarly, agents that
affect the interaction of STAT3 and the cytoskeleton may also
inhibit the transcriptional function of STAT3.
26 In any case, it is
clear that this type of cell-based functional screen has been very
productive in terms of identifying both inhibitors and activators
of STATs that may be therapeutically important.
Identification of STAT3 Inhibitors
STAT3 phosphorylation inhibitors: targeting kinases. One of
the first published screens using this approach, a diverse chemical
library largely comprised of known bioactive molecules was
assessed for its ability to inhibit STAT3-dependent luciferase
activity.
16 Libraries of bioactive compounds provide both
structural diversity as well as an opportunity to evaluate
compounds that have often been administered to humans, and
for which extensive pharmacokinetic data may be available. Using
this approach, nifuroxazide, a drug used in many countries to treat
diarrheal illnesses, was identified as an inhibitor of STAT3
transcriptional function with an EC50 of approximately 3 mM. At
this concentration, nifuroxazide showed no inhibition of NFkB-
dependent transcriptional activity in a counter-screen. In
analyzing the mechanism of action of nifuroxazide, it was found
that this compound inhibited the activating tyrosine phosphor-
ylation of STAT3, while showing no effect on phosphorylation of
STAT3 at serine-727. Furthermore, nifuroxazide inhibited the
tyrosine phosphorylation of both Tyk2 and JAK2 (though not
JAK1), suggesting that it might be acting as a JAK family tyrosine
kinase inhibitor. In multiple myeloma cells, a disease driven
commonly by STAT3 activation, nifuroxazide decreased expres-
sion of the pro-survival gene Mcl-1, and decreased the survival of
both myeloma cell lines with activated STAT3 and primary
samples from patients. The survival of myeloma cells is enhanced
by co-culturing with bone marrow stromal cells.
27 Through both
cell-cell contact and the release of soluble factors, stromal cells
promote the viability and drug resistance of myeloma cells, often
through STAT3-dependent pathways.
28 Notably, nifuroxazide
showed equal effects in inhibiting myeloma cell survival regardless
of the presence of stromal cells.
Although inhibition of STAT3 can directly lead to a loss of
viability of myeloma cells, it may also decrease the threshold for
these cells to undergo apoptosis when simultaneously treated with
agents with distinct mechanisms of action. Reflecting this
property, co-treatment of myeloma cells with nifuroxazide and
either the histone deacetylase inhibitor depsipeptide (romidepsin)
or the MEK inhibitor U0126 showed enhanced cytotoxicity.
These findings provided proof-of-concept that a transcription
based assay for identifying STAT3 inhibition could identify active
compounds with clinical relevance.
STAT phosphorylation inhibitors: non-kinase targets. A
second inhibitor of STAT tyrosine phosphorylation that was
identified through a cell-based transcriptional screen is pimo-
zide.
29 Pimozide has been used clinically as a neuroleptic, and is
approved by the FDA in the United States for the treatment of
symptoms of Tourette syndrome. Pimozide was found to
decrease STAT5 phosphorylation in CML cell lines, in which
the fusion oncoprotein Bcr-Abl1 leads to constitutive phosphor-
ylation of STAT5 and increased expression of STAT5 target
genes. Pimozide also inhibits STAT5 activation driven by
mutated JAK2 in myeloproliferative neoplasms.
30 However,
pimozide is not a kinase inhibitor. It does not inhibit JAKs,
Abl1 or Src family members in in vitro kinase assays, nor does it
inhibit all signaling pathways downstream of activated kinases.
For example, in CML models, kinase inhibitors such as imatinib
decrease the phosphorylation and activation not only of STAT5,
but of MAP kinase also. By contrast, pimozide does not decrease
MAP kinase phosphorylation, and actually leads to an increase in
this activating phosphorylation. Although the reason for this
effect has not yet been elucidated, it may relate to the fact that
many STAT target genes are negative regulators of signaling
events,
7 and the loss of these regulators leads to increased activity
of other pathways. A correlate of this observation is that the
combination of a STAT inhibitor such as pimozide and an
inhibitor of the MAP kinase pathway, like the MEK inhibitor
U0126, would be expected to be particularly effective in killing
CML cells. In fact, this combination leads to synergistic killing
in cell line models.
Like kinase inhibitors, pimozide decreases expression of STAT5
target genes, and decreases viability of CML cell lines and primary
CML cells through induction of apoptosis. Since STAT5 is
involved in the response to cytokines in normal hematopoiesis,
the question arises as to whether inhibition of STAT5 would be
expected to have toxicity to normal cells. The survival of normal
mature hematopoietic cells, such as peripheral blood mononuclear
cells, is unaffected by pimozide. Furthermore, in vitro colony
formation by CD34
+ cells from healthy donors is only minimally
affected by pimozide. These findings also reflect the fact that in
clinical use pimozide has not been found to have hematopoietic
toxicity.
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has shown efficacy in other myeloid malignancies. For example, in
AML, another disease in which aberrant STAT activation
(STAT5 and/or STAT3) is common, pimozide can also decrease
STAT5 phosphorylation and STAT5-dependent gene expres-
sion.
31 Similar to CML, in AML cell lines driven by an activating
mutation in the cell surface tyrosine kinase Flt3, pimozide shows
synergistic effects on loss of viability and induction of apoptosis
when combined with kinase inhibitors targeting Flt3, including
midostaurin (PKC412) and the multi-kinase inhibitor sunitinib.
Notably, pimozide was non-toxic and highly active in a murine
model of mutant Flt3-driven leukemia.
Among the advantages of targeting a STAT is the ability to
overcome the resistance to kinase inhibitors that commonly
develops in clinical practice.
32 In CML, a range of point
mutations arising within Bcr-Abl1 can mediate resistance to
imatinib. One mutation in particular, T315I, confers resistance to
all of the presently available approved kinase inhibitors. If STAT5
is a key downstream mediator of the effects of Bcr-Abl1, then it
would be predicted that inhibition of STAT5 would be equally
effective in the presence of such a mutation. In fact, the sensitivity
to pimozide of hematopoietic cells rendered growth factor
independent by transfection of Bcr-Abl1 is identical regardless
of whether the cells express the wild-type fusion protein or the
mutant form carrying T315I.
29 This ability to overcome the
effects of even these so-called “gatekeeper” mutations is a principal
advantage of a STAT inhibitor like pimozide. In contrast to
kinases, naturally occurring mutations in STATs are extremely
rare, perhaps reflecting the limited tolerance of transcription
factors to structural modification. This suggests that resistance to
drugs targeting STATs may be much less likely to occur through
mutations in the STATs themselves.
It is sometimes suggested that blocking sequential steps in the
same biological pathway is unlikely to provide any therapeutic
benefit over complete inhibition of a single step in that pathway.
However, one might predict that the combination of a STAT
inhibitor and an inhibitor of an upstream kinase might have
several benefits. First, if there is incomplete inhibition of either
target, perhaps related to pharmacokinetic considerations, then
the combination may be more likely to suppress the entire
pathway more completely. In fact, the combination of imatinib
and pimozide leads to a synergistic induction of apoptosis and
decrease in viable cell number.
33 This is similar to what is seen
when pimozide is combined with Flt3 kinase inhibitors in models
of AML, or with JAK2 inhibitors in models of myeloproliferative
neoplasms.
30,31 Second, co-administration of a kinase inhibitor
and a STAT5 inhibitor would also be expected to remove the
selective pressure for the emergence of resistance-causing kinase
mutations or mutational activation of another kinase. Thus, dual
inhibition of STATs and upstream kinases may be a particularly
effective therapeutic combination.
One final consideration concerns the fact that patients with
CML generally need to continue treatment with kinase inhibitors
indefinitely to suppress the leukemia. The concern is that a small
population of self-renewing cells, sometimes referred to as
leukemic stem cells, is able to persist in the presence of kinase
inhibitors. These cells may be relatively quiescent or they may be
able to maintain activation of STAT5-dependent survival path-
ways through alternative signaling pathways. If this latter
hypothesis is correct, then it would be predicted that an inhibitor
directed at STAT5 specifically might have efficacy against this
critical population. In fact, pimozide completely inhibits the
development of in vitro colonies from CD34
+ cells from patients
with CML,
33 raising the possibility that STAT-directed therapy
might be able to eradicate these putative tumor stem cells.
One other aspect of pharmacological STAT inhibition has
important implications for understanding both biology and
therapeutic strategies. In developing drugs, a key pharmacological
issue is what drug levels must be achieved to functionally inhibit
the target, and for what period of time is it necessary to maintain
these levels to achieve a therapeutic effect. Since STATs regulate
pro-survival genes whose continued expression is necessary to
maintain the viability of a cancer cell, it may be that even
intermittent inhibition of STAT-dependent transcriptional activ-
ity is sufficient to have therapeutic benefit.
30 This can be
important for drugs that have short half-lives in vivo or that may
have an unfavorable side effect profile. There is evidence that even
transient exposure to pimozide may be sufficient to trigger cell
death in myeloid neoplasms, and further understanding of this
therapeutic interval is likely to be important for clinical translation
of this approach.
30
STAT inhibitors that do not affect phosphorylation. Although
much effort in the development of STAT inhibitors has focused
on compounds that block the activating tyrosine phosphorylation,
a particular advantage of a transcription-based screening approach
is that it can identify molecules that specifically inhibit the
function of STATs without altering tyrosine phosphorylation.
This has a number of advantages. First, it can help identify
indirect modulators of STAT transcriptional function, which can
reveal new insights about other aspects of this signaling pathway,
and may reveal unappreciated targets for therapeutic devel-
opment. One such inhibitor that emerged from a screen of known
bioactive compounds is pyrimethamine, an anti-microbial
drug.
11,34 Pyrimethamine, which is FDA-approved for the
treatment of malaria and toxoplasmosis, inhibits STAT3
transcriptional activity without affecting STAT3 tyrosine phos-
phorylation at low micromolar concentrations. Pyrimethamine
also shows no effects on the highly homologous transcription
factor STAT5. Reflecting its mechanism-specific effects, pyr-
imethamine causes a loss of viability of multiple myeloma cells
characterized by constitutive STAT3 activation, but not those that
lack this molecular hallmark. Furthermore, as predicted by its
good safety record in humans, pyrimethamine has no effect on the
viability of peripheral blood mononuclear cells (PBMCs) from
healthy donors. Finally, high throughput profiling of human
cancer cell lines has suggested that pyrimethamine may be
effective against a broad spectrum of cancers.
11
Given that pyrimethamine can inhibit STAT3 transcriptional
function independent of STAT3 tyrosine phosphorylation, it
would be expected to have activity in cancers characterized by
STAT3 that is transcriptionally active through an alternate
mechanism like serine phosphorylation, as is seen in chronic
296 JAK-STAT Volume 1 Issue 4lymphocytic leukemia (CLL).
35,36 Given that pyrimethamine is
already known to be safe in humans, and that concentrations
sufficient to block STAT3 function can be achieved with standard
dosing regimens, a clinical trial of pyrimethamine in CLL has
been initiated (ClinicalTrials.gov identifier: NCT01066663).
Since most patients with CLL have large numbers of circulating
leukemia cells, a clinical trial in this disease also affords the
opportunity to recover tumor cells from patients on therapy to
determine whether STAT3-dependent transcriptional function is
being inhibited in the patients. This information will be critical
for designing subsequent studies employing STAT inhibition.
Inappropriate STAT3 activation is also found in a hyperpro-
liferative though non-neoplastic disease, polycystic kidney disease
(PCKD). Pyrimethamine shows therapeutic effects in in vitro and
animal models of this disease, though at concentrations in the
mid-micromolar range.
34 At these concentrations, pyrimethamine
does cause some decrease in STAT3 tyrosine phosphorylation and
a corresponding increase in STAT1 phosphorylation, so this drug
may have overlapping concentration-dependent mechanisms for
inhibiting STAT3 function.
Activation of STAT1 as a Therapeutic Target
STAT1, which mediates the effects of interferons, can exert
cytostatic, pro-apoptotic and anti-angiogenic effects.
37,38
Consequently, STAT1 can oppose some of the pro-tumorigenic
effects of STAT3, and may exert a therapeutic effect in cancer.
The nature of transcription-based screens makes it equally easy to
identify compounds that activate or enhance transcriptional
function as those that inhibit it. This approach was used to
identify activators of STAT1-dependent transcription from a
chemical library.
39 One compound identified through this
approach, 2-(1,8-naphthyridin-2-yl)phenol (2-NP), increases
expression of endogenous STAT1 target genes. 2-NP exerts this
effect by prolonging the time that STAT1 remains phosphory-
lated after being activated. Related to this effect, 2-NP enhances
the ability of interferon-c to inhibit the proliferation of tumor
cells. As predicted by its mechanism, it only exerts this effect in
cancer cells expressing STAT1, but not in cancer cells that lack
expression of this transcription factor.
Alternative Approaches to Screens
for STAT3 Inhibitors
Cell-based assays for drug discovery have generally focused on
mammalian cells, for their obvious relevance to human cellular
physiology and disease. However, cells obtained from other model
organisms may have certain advantages, such as reduced genomic
redundancy, that may be beneficial. A rudimentary STAT
signaling system is present in Drosophila, in which ligands of
the Unpaired family interact with a single receptor to activate one
JAK, which can phosphorylate and activate a single STAT. Using
Drosophila cells with a stably introduced STAT-responsive
luciferase reporter, a compound library of polysubstituted
imidopiperidines was screened.
40 To exclude non-specific toxicity,
a Renilla luciferase reporter, whose activity can be distinguished
from the standard firefly luciferase, was also introduced into these
cells. Using this approach, a compound termed AUH-6–96 was
identified that decreased STAT transcriptional activity through
inhibition of phosphorylation. This compound was then found to
decrease IL-6 induced STAT3 phosphorylation as well as the
constitutive STAT3 phosphorylation found in the Hodgkin
lymphoma cell line L540, the breast cancer cell line MDA-MB-
468 and the prostate cancer cell line DU145. AUH-6–96
decreased expression of STAT3-dependent pro-survival genes
such as Bcl-xL and Bcl-2 and induced apoptosis in L540 cells.
Suggesting that its effects are mechanism-specific, this compound
decreased viability of cancer cell lines with activated STAT3, but
not those without. These findings suggest that a broad array of
cellular systems may be useful in identifying signaling inhibitors.
Although a transcription-based assay has been very productive
and has the capability of uncovering diverse mechanisms to
modulate STAT function, other cell-based approaches have also
been successfully employed to identify STAT3 inhibitors. One
strategy is to use antibodies specific for the tyrosine phosphory-
lated form of STAT3 to perform a well-based “cytoblot” to detect
compounds that inhibit this activating phosphorylation event.
Using this approach to screen the National Cancer Institute
Diversity Set of 1992 compounds, JSI-124 (curcurbitacin I), was
identified and validated as a STAT3 phosphorylation inhibitor,
which showed therapeutic activity in cell culture-based and animal
models of STAT3-driven tumors.
41
A second approach that has been used employs microscopic
imaging to identify compounds that block cytokine-induced
nuclear translocation of a STAT3 construct that expresses a
fluorescent protein. This approach cannot only identify inhibitors
of STAT3 tyrosine phosphorylation, but it can also potentially
identify inhibitors targeting proteins necessary for the nuclear
translocation of STAT3. Using this approach to screen the
National Cancer Institute Diversity Set, SD-1029 was identified,
and found to be an inhibitor of STAT3 tyrosine phosphoryla-
tion.
42 SD-1029 appears to act by inhibiting the kinase JAK2,
which mediates STAT3 tyrosine phosphorylation in a range of
tumor types. In addition, this compound decreases expression of
STAT3 target genes and induces apoptosis in breast and ovarian
cancer cell lines. Reflecting the fact that many STAT3 target genes
promote survival and resistance to chemotherapy, SD-1029
enhances apoptosis when combined with the cytotoxic drug
paclitaxel. These types of combinations may be an important
strategy for the optimal clinical translation of STAT inhibitors,
which may not be sufficient to induce maximal cell killing on
their own.
Elucidating the Mechanism of Action
of Screen-Derived Compounds
As noted, chemical library screens have been very productive in
identifying molecules that modulate transcription factor function,
and have even allowed the identification of a STAT3 inhibitor
that is currently in a clinical trial. Given that the assay is agnostic
as to the mechanism of action of a compound, it allows the
identification of molecular probes that modulate a variety of
www.landesbioscience.com JAK-STAT 297mechanisms by which STATs are regulated. A major shortcoming
of this approach, however, is that the direct target of the
compounds identified may not be immediately apparent. The
target of compounds that act through kinase inhibition, like
nifuroxazide, can be deconvoluted relatively rapidly. However, the
proximal target of a compound like pimozide, which decreases
STAT tyrosine phosphorylation without obvious kinase inhib-
itory activity, may be more obscure. Such an agent may inhibit a
co-activator of a kinase or it may enhance the activity of a negative
regulator of STAT signaling, such as a phosphatase. It can be even
more difficult to elucidate the target of a compound like
pyrimethamine, which decreases STAT3 transcriptional function
without necessarily affecting STAT tyrosine phosphorylation or
DNA binding. Presumably compounds in this class are inhibiting
a co-activator of transcription that partners with STAT3.
A number of strategies can be employed to identify the direct
target of these compounds including testing of individual
candidates, using derivatized drugs for affinity isolation of targets,
performing RNA interference screens to identify gene products
necessary for the function of a compound, or analyzing cell lines
selected for resistance to the effect of an agent. However, these
approaches can be time-consuming, and do not guarantee success.
As is the case with pyrimethamine, one can argue that it is not
always necessary to identify a direct target to proceed to a clinical
trial with a functionally active STAT inhibitor. However, both to
understand the biological significance of a chemical probe and to
fully exploit its therapeutic potential, direct identification of a
target will almost always be a necessary, though challenging,
component of evaluation of compounds identified through this
approach.
Conclusion
An abundance of evidence supports the roles of STATs,
particularly STAT3 and STAT5, as key mediators of oncogenic
signaling pathways. Since STATs can be inhibited in normal cells
without significant consequence, STATs represent very appealing
targets for the rational molecular therapy of cancer. Cell-based
functional assays of STAT transcriptional activity can allow the
identification of specific and effective inhibitors of individual
STATs. Furthermore, this approach can allow the identification of
unappreciated regulators of STAT signaling, novel targets for
therapeutic intervention and lead compounds for clinical trials
evaluating the efficacy of this approach.
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